BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38466670)

  • 1. Burkitt lymphoma: The effect of age, sex and delay to diagnosis on treatment completion and outcome of treatment in 934 Patients in Cameroon.
    Hesseling PB; Afungchwi GM; Njodzeka BW; Wharin P; Kouya FN; Kruger M
    PLoS One; 2024; 19(3):e0299777. PubMed ID: 38466670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy.
    Hesseling PB; Njume E; Kouya F; Katayi T; Wharin P; Tamannai M; Achu P; Kidd M; McCormick P
    Pediatr Hematol Oncol; 2012 Mar; 29(2):119-29. PubMed ID: 22376015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate.
    Hesseling P; Molyneux E; Kamiza S; Israels T; Broadhead R
    Ann Trop Paediatr; 2009 Mar; 29(1):29-34. PubMed ID: 19222931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma.
    Depani S; Banda K; Bailey S; Israels T; Chagaluka G; Molyneux E
    Pediatr Blood Cancer; 2015 Nov; 62(11):1929-34. PubMed ID: 26052841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
    Koffi GK; Tolo A; Nanho DC; N'dathz E; Kouassi MY; N'Diaye FD; Kouakou B; Meité N; Ayemou R; Sekongo M; Kouehion P; Meité M; Tea ND; Sangaré A; Sanogo I
    Int J Hematol; 2010 Jun; 91(5):838-43. PubMed ID: 20480270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d'Oncologie Pédiatrique.
    Bouda GC; Traoré F; Couitchere L; Raquin MA; Guedenon KM; Pondy A; Moreira C; Rakotomahefa M; Harif M; Patte C
    J Glob Oncol; 2019 Nov; 5():1-9. PubMed ID: 31794283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
    Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
    Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endemic Burkitt Lymphoma: Long-term Outcome in 87 Patients Who Presented With Paraplegia in Cameroon.
    Hesseling PB; Mbah G; Kouya F; Kimbi C; Nfor P; Kaah J; Kuruvilla R; Best A; Wharin P
    Pediatr Hematol Oncol; 2015; 32(8):525-8. PubMed ID: 26606160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
    Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
    Diviné M; Casassus P; Koscielny S; Bosq J; Sebban C; Le Maignan C; Stamattoulas A; Dupriez B; Raphaël M; Pico JL; Ribrag V; ;
    Ann Oncol; 2005 Dec; 16(12):1928-35. PubMed ID: 16284057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda.
    McGoldrick SM; Mutyaba I; Adams SV; Larsen A; Krantz EM; Namirembe C; Mooka P; Nabakooza S; Ndagire M; Mubiru K; Nabwana M; Nankinga R; Gerdts S; Gordon-Maclean C; Geriga F; Omoding A; Sessle E; Kambugu J; Uldrick TS; Orem J; Casper C
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27813. PubMed ID: 31157502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
    Galicier L; Fieschi C; Borie R; Meignin V; Daniel MT; Gérard L; Oksenhendler E
    Blood; 2007 Oct; 110(8):2846-54. PubMed ID: 17609431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
    Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
    Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution's experience.
    Muwakkit SA; Razzouk BI; Shabb NS; Hancock ML; Dabbous I; Firzli S; Abboud MR
    J Pediatr Hematol Oncol; 2004 Nov; 26(11):749-53. PubMed ID: 15543011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2000 Burkitt lymphoma trial in Malawi.
    Hesseling P; Broadhead R; Mansvelt E; Louw M; Wessels G; Borgstein E; Schneider J; Molyneux E
    Pediatr Blood Cancer; 2005 Mar; 44(3):245-50. PubMed ID: 15547922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
    Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
    Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.